The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global 3D bioprinting market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
3D bioprinting refers to an additive manufacturing technique used for the development of precise anatomical tissues through the decomposition of cell-based bio-inks. 3D bioprinting involves various deposition and assembling processes, such as direct and laser writing, microstamping, photolithography, stereolithography, electro-printing and inkjet deposition. The bio-inks are manufactured using living cells, biomaterials and active biomolecules to create 3D structures of tissues and organs. The printer deposits multiple layers of biomaterials to build complex bodily structures, such as bones, skin, vascular grafts, tracheal splints, heart tissues and cartilages. These printed structures are assembled and bonded using dissolvable gel or collagen scaffolds to support and mold the cells in the desired shape.
The increasing prevalence of chronic respiratory and cardiovascular disorders (CVDs) across the globe is one of the key factors driving the growth of the market. Moreover, the rising requirement for regenerative medicines, cancer therapeutics and stem cell solutions is providing a thrust to the market growth. 3D bioprinting is widely used for liver modeling and development of various bone, tissue and medical implants. In line with this, the increasing consciousness among the masses to minimize animal testing is also contributing to the market growth. Cosmetic manufacturers use bio-printed hair follicles and skin grafts to clinically test the products on human-like tissues. Additionally, various technological advancements, such as the development of organ-on-a-chip, are acting as other growth-inducing factors. These innovative bio-printed structures enable 3D in-vitro analysis of the bodily functions and fabrication of artificial organs and tissues for regenerative medicine and tissue engineering. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the increasing adoption of magnetic levitation technology for toxicity screening and vascular muscle printing, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global 3D bioprinting market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on component, application and end user.
Breakup by Component:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3D Systems Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM – Gesellschaft für Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU and Stratasys Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Component, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3D Systems Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM – Gesellschaft für Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU and Stratasys Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at